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Introduction 
 
Annually, influenza viruses are associated with a 
substantial disease burden worldwide. Since its 
emergence in April 2009, an outbreak of influenza 
A (H1N1) pdm09 began in Mexico and spread 
rapidly across many countries, including Spain. A 
pandemic was declared by WHO on 11 June 2009.  
Since then, our knowledge about influenza A 
(H1N1) in pregnancy has increased enormously. 
Much more attention has been paid to pregnancy 
issues because it is known that pregnant women 
(PW) are more susceptible to developing serious 
influenza complications (1-4), besides suffering 
adverse effects during pregnancy; e.g. spontaneous 
miscarriage and preterm delivery (5-7). The influ-
enza A (H1N1) pdm09 virus extraordinarily in-
creased both the hospital admission rate among 
PW and the number of maternal mortalities in the 
USA, Australia, New Zealand, South Africa, Brazil, 
Greece, Peru, Chile, France and Turkey during the 
pandemic (5, 9, 11-20). Given the high incidence 
rates, the medical costs incurred during the 2009 
pandemic were considerable everywhere (23, 24).   
Pregnant women are more susceptible to compli-
cations from influenza, which often results in ad-
mission to hospital. For all these reasons, PW 
were considered an at-risk group. Studies of the 
consequences for pregnancy and the fetus, both 
for the influenza and its treatment, are also im-
portant in the context of public health (8, 9). 
The Spanish Ministry of Health (10) recom-
mended giving priority to immunising people at 
increased risk of influenza complications in influ-
enza A (H1N1)pdm09, such as PW in any tri-
mester of pregnancy (10). Although prioritisation 
was important, these recommendations were 
based on the medical literature, and their potential 
cost-effectiveness was largely unknown. 
Therefore, up-to-date information on the cost of a 
non-vaccinated risk group, such as pregnant wom-
en, and non-pregnant women (NPW), will im-
prove the prioritisation and acceptability of in-
fluenza vaccination uptake, inform policy-makers 
in Spain, and could be useful for making similar 
decisions in other counties.  
In order to prevent pandemic influenza A 
(H1N1)pdm09 from spreading, the Spanish gov-
ernment applied not only its regular health policies, 
such as quarantine, isolation and hygiene cam-
paigns, but also a special protocol in at-risk groups 
such as PW (e.g., offering vaccination) (21, 22). 
Nonetheless, there were no data available on the 
related cost of the virus infection to allow a com-
parison between non-vaccinated PW and NPW of 
childbearing age to be made. 
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Knowing the health cost incurred by women of 
childbearing age will allow us to: 1) learn what 
spending has resulted from influenza A (H1N1) 
pdm09 in Spain in these important groups of 
women; 2) improve health management strategies 
(prioritisation of vaccines, control programs, etc.) 
in future epidemics; 3) know its relevance for fu-
ture health policy and practice decisions. 
Thus, our aim was to estimate and compare direct 
healthcare costs (medical visits, medication, diag-
nosis tests, and hospitalisation) and indirect 
healthcare costs (work absenteeism) that resulted 
from pandemic influenza A (H1N1) pdm09 in PW 
with those resulting in non-vaccinated NPW of 
childbearing age.  
 
Methods 
 
Study population and design 
This work was a pharmaco-epidemiological study 
of health costs that formed part of a multicentre 
matched case-control study of influenza A (H1N1) 
pdm09 infection carried out in 28 hospitals in sev-
en Spanish Autonomous Communities (Andalusia, 
the Basque Country, Castile and Leon, Catalonia, 
Madrid, Navarre and the Valencian Community). 
A protocol was followed whose objective was to 
determine the impact of influenza A (H1N1) 
pdm09 on the Spanish population between 1 No-
vember 2009 and 28 February 2010 during the 
pandemic wave (16). The healthcare cost (€) for 
unvaccinated women of childbearing age with in-
fluenza A (H1N1) pdm09 was evaluated. 
For the base case analysis, it was assumed that of 
those who developed clinical symptoms of (H1N1) 
pdm09, some would choose no treatment, while 
others would seek treatment from general practi-
tioners (GPs). Those who received treatment 
could be prescribed medication for symptomatic 
relief, antibiotics or antivirals for complementa-
tion, or could be admitted to hospital. 
Associated outcomes (consequences) and costs 
were summed for each group, these being: PW 
and NPW; the cost of each intervention (e.g. cost 
of treatment); the cost of each consequence (e.g. 
cost of hospitalisations). They all constituted 
healthcare costs. Inputs were the requirements in 
managing both groups of women. Outcome 
measures were healthcare costs.  
 
Sample selection  
In all, 3,790 influenza A (H1N1) pdm09-infected 
subjects were surveyed. Of these, 1,165 were 
women of childbearing age (between 15-44 years 
old). They had visited the participating hospitals 
during the study period. Their influenza A (H1N1) 
pdm09 virus infection was confirmed by a Reverse 
Transcriptase Polymerase Chain Reaction (RT-
PCR) in a microbiology laboratory. The inclusion 
criteria considered for this study were having been 
microbiologically confirmed to be infected by the 
virus and being hospitalised for more than 24 h. 
Of the 219 women who met the inclusion criteria, 
170 were NPW and 49 were PW. None had been 
vaccinated against seasonal or pandemic influenza 
viruses during the 2009-2010 seasons. 
The economic burden resulting from pandemic in-
fluenza A (H1N1) pdm09 was estimated by an in-
cidence approach. The associated direct healthcare 
costs and indirect costs deriving from absenteeism 
from work were calculated from a healthcare pro-
vider’s perspective. Since consequences of influ-
enza generally occur during a short period of time, 
the time horizon was set at 4 months. Due to this 
short period, discount rates were not needed. 
Therefore, we considered the healthcare costs per 
hospitalised patient as the reported Surveillance 
System number of severe influenza cases coordi-
nated by the Centre for Health Alerts and Emer-
gencies of the Spanish Ministry of Health and So-
cial Policy (inpatients) (5,16). 
 
Data collection  
Information was collected at two time points: 
baseline (Primary Care General Practitioner (GP) 
or hospital) and follow-up (hospitalisation time). 
The variables measured at the baseline referred to 
the 7 days (medical visit index (outpatients)) be-
fore hospital admission (inpatients) and the dura-
tion of this hospitalisation. As this study started 
after the pandemic had begun, this information 
was collected retrospectively: the median time 
from the medical visit index or hospital admission 
to the time that information was collected was 125 
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days (IQR 89-166). The following variables were 
obtained from telephone interviews or during the 
personal face-to-face interviews conducted with 
patients diagnosed and hospitalised with the influ-
enza A (H1N1) pdm09 virus: age; if they were 
pregnant or not; if so, trimester of pregnancy; 
city/town of residence; level of education; marital 
status; days of absenteeism from work. Other var-
iables were also obtained from medical records for 
hospital databases: number of medical visits; phar-
macological treatment (doses were not available); 
diagnostic tests; Health Scale SF-36; length of stay 
of inpatients in a hospitalisation unit. We also used 
medical risk, which was evaluated by each patient’s 
GP in relation with patient co-morbidity. The 
same variables were recorded for PW and NPW, 
except for weeks of gestation, obtained for only 
PW. 
 
Estimating unit costs 
While information on the management of patients 
and pharmacological treatment was collected, the 
specific drug and dose were not available. So we 
assumed utilisation rates in accordance with rec-
ommendations from Clinical Practice Guidelines 
(17,18). The Spanish National Health System does 
not have information on unit costs. Hence alter-
native sources were considered for the monetary 
evaluation of healthcare resources utilisation (24). 
The unit costs of the considered healthcare re-
sources included the retail price of the drugs pub-
lished in a Spanish Vademecum (25). We adjusted 
treatment to a minimum dose (1/day), and we 
evaluated complete treatment for Oseltamivir (5-
day treatment). The actual costs of the diagnostic 
tests were calculated using the price list offered by 
the Hospital Clinic of Barcelona and the mass me-
dia publications of the pandemic vaccine price (26) 
The cost per day of hospitalisation was obtained 
from one of the participating hospitals (Hospital 
del Mar of Barcelona) during the same study pe-
riod (24). This hospital has a clinical-cost evalua-
tion system that establishes hospital expenses ac-
cording to the hospitalisation unit (27). Costs per 
day in an intensive care unit (ICU) and on a gen-
eral ward were calculated separately by dividing 
total expenses by the total number of hospitalisa-
tion days in each unit. We used the cost estimated 
by all the regions participating in this study (26, 28, 
29). For the cost per day derived from absentee-
ism from work, we evaluated only 1 day of absen-
teeism using the national estimation (27). 
 
Statistical analysis 
An economic descriptive analysis was done to 
characterise the study population (women of 
childbearing age: PW vs. NPW). The number and 
percentage of patients who partook in healthcare 
resources utilisation and absenteeism from work 
were informed. Mean utilisation frequencies and 
standard deviations (SD) were calculated. Patients' 
absenteeism from work was estimated from those 
who were working when the disease started. 
The direct costs associated with healthcare re-
sources utilisation and the indirect costs associated 
with patients’ absenteeism from work (loss of in-
come) were estimated by multiplying the fre-
quency of utilisation by each unit cost. The mean 
cost due to the utilisation of each resource type 
was calculated for all the patients. Costs per pa-
tient are presented in € (2009) in accordance with 
unit costs, along with the frequency of social and 
healthcare resources utilisation.  
All the data were included and analyses were per-
formed with the SPSS software, v.19 (SPSS Inc., 
Chicago, IL, USA). Chi-square tests were per-
formed to compare differences between PW and 
NPW. The normally distributed continuous varia-
bles were compared between PW and NPW by t-
tests, and P values of <0.05 were considered sta-
tistically significant. 
 
Ethical statement 
The information collected in the present study has 
been treated confidentially according to legislation 
currently in force. The project was presented to 
the Ethics and Research Committee (CEIC, in 
Spanish) of the Mar Parc de Salut Consortium of 
Barcelona (Spain) as the CIBERESP-linked centre, 
and to the CEICs of all the other participating 
hospitals. The project was approved by them all. 
The study followed the ethical standards of the 
Declaration of Helsinki. All the participants were 
invited to sign an informed written consent after 
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explaining the aim and concerns of the study to 
them. Data sheets were coded to ensure anonym-
ity and confidentiality of patients’ data. 
 
Result 
 
Patients’ characteristics 
Table 1 describes the characteristics of the non-
vaccinated PW and NPW of childbearing age (15-
44 yr old) infected with the influenza A (H1N1) 
pdm09 virus in Spain (2009-2010). A similar mean 
age was obtained for both groups: 33.2 (SD=9.3) 
years for NPW and 30.8 (SD=6.4) for PW. When 
considering marital status, married women pre-
dominated with 75.5% and 49.5%, respectively. A 
higher proportion of PW had completed second-
ary or higher education vs. NPW (91.8% vs. 63.6%, 
respectively). A significant difference in medical 
risk was also observed despite the moderate risk 
of becoming infected by the (H1N1) pdm09 virus 
category being more frequent in both PW and 
NPW. PW were mostly in their third trimester of 
pregnancy (75.5%). We can see that NPW showed 
a high medical risk (20.4%) vs. PW 6.1% (P < 
0.001). The Health Scale SF-36 value was similar 
in both groups (P = 0.480). 
 
Table 1: Characteristics of PW and NPW infected with pandemic influenza A (H1N1) pdm09 virus in Spain (2009-2010) 
 
Variable NPWa 
(n= 170) 
N (%) 
PWa 
(n=49) 
N (%) 
P b 
Age, mean (SD) 33.2 (9.3) 30.8 (6.4) 0.110 
Age group (years)    
 <20  20 (11.8) 14 (28.6) 0.001 
 20-29  70 (41.2) 3 (6.1) 
 30-34 19 (11.2) 19 (38.8) 
 >34  61 (35.9) 13 (26.5) 
Trimester of pregnancy    
 First (week 1-12)  4 (8.2)  
 Second (weeks 13-25)  8 (16.3)  
 Third (weeks 26-40)  37 (75.5)  
Autonomous Community    
 Andalusia 24 (20.5) 17 (34.7)  
0.070  Castille and León 9 (7.7) 3 (7.2) 
 Catalonia 36 (30.8) 9 (18.4) 
 Basque Country 15 (12.8) 2 (4.1) 
 Madrid 20 (17.1) 15 (30.6) 
 Valencian Community 6 (5.1) 2 (4.1) 
 Navarre 7 (6.0) 1 (2.0) 
Level of education    
 None /primary studies 59 (36.4) 4 (8.2) <0.001 
 Secondary/higher education 103 (63.6) 45 (91.8) 
Marital status    
 Single 53 (50.5) 11 (24.4)  
0.009  Married 52 (49.5) 34 (75.6) 
Medical risk    
 Low 26 (26.5)   
0.001  Moderate 52 (53.1) 46 (93.9) 
 High 20 (20.4) 3 (6.1) 
Health Scale (SF-36), mean (SD)    
Previous diagnosis 69.3 (26.5) 72.7 (29.4) 0.401 
Influenza 53.3 (30.6) 57.9 (31.6) 0.480 
a Percentages refer to the actual number of responses/data for each group/ bChi-square test./ANOVA/SD, standard deviation; 
N, number  
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Healthcare economic burden 
Table 2 describes the healthcare costs related to 
women’s requirements (according to patient man-
agement) for pandemic influenza A (H1N1) 
pdm09 who were not vaccinated and attended the 
hospital. The most widely used previous treatment 
was antibiotics and antipyretics in NPW, while 
only eight of the 49 PW cases studied (16%) used 
antibiotics. The cost of medical visits was higher, 
especially for NPW. Of the medication required 
by hospitalised patients, Oseltamivir and ibu-
profen-acetaminophen stood out in both PW and 
NPW. The most commonly used diagnostic tests 
done were X-rays in NPW and PCR in the controls. 
Notwithstanding, differences were found in days of 
absenteeism from work depending on the Spanish 
Autonomous Community to which the patient be-
longed. Table 3 summarises the direct, indirect and 
total costs per patient. Each case in the NPW group 
generated a higher individual total cost (€4,689.4) 
than the PW group (€2,945.07). The most important 
difference was due to higher direct costs. 
 
Table 2: Healthcare costs for women infected with the pandemic A (H1N1) 2009 influenza virus in Spain (2009-2010) 
 
  NPW (n=170)  PW (n=49) 
Variable Unit 
Cost 
N u/at (u/at)/N Cost/p(€)  N u/at (u/at)/N Cost/p(€) 
Previous Treatment*           
Antibiotic 1.61 83 83 0.48 0.77  8 19 2.37 3.82 
Oral glucocorticoids  0.62 31 31 0.18 0.11      
Inhaled glucocorticoids 0.05 71 71 0.41 2.05      
AntiH2  10 10 0.06 5.40      
Antipyretics 0.35 94 94 0.55 0.19      
Medical visits           
Total number of visits   338     42   
Primary care GP’s 37.5 116 166 1.43 53.62  15 23 1.53 57.37 
Home medical care 58.5 17 17 1.0 58.50  2 2 1.0 58.50 
Occupational care 100 3 5 1.67 167.00  1 1 1.0 100.00 
Outpatients office 167.3 12 14 1.17 163.33  3 3 1.0 139.60 
Primary care ED 87.7 44 52 1.18 103.48  5 7 1.4 122.78 
Hospital ED  139.6 71 84 1.18 164.72  6 6 1 139.6 
Cost per day of hospitalisation 505.2 281 2122 7.55 3814.26  45 198 4.4 2222.8 
Medication*           
Oseltamivir (day of treatment for 
adult)** 
6.514 110 550 5 32.57  32 160 5 3.26 
Antibiotics (day of treatment)  1.61 95  0.55 0.88  16   0.52 
Oral glucocorticoids (day of 
treatment) 
0.62 44  0.25 0.15  2   0.02 
Ibuprophen-acetaminophen (day 
of treatment ) 
0.35 96  0.56 0.19  33   0.23 
Diagnosis Tests           
Radiography (front and side views) 21.3 170 272 1.6 34.8  21  0.42 9.12 
Computed Tomography without 
contrast 
120.2 13  0.07 9.19  0    
Laboratory (RT-PCR) 9.6 170 203 1.19 11.46  38  0.77 7.44 
Cost per work absenteeism (day)#†         
Andalusia 129.2 27   20.52  7   18.46 
Catalonia 134 57   44.92  3   8.20 
Castille and Leon 129.4 9   6.85  2   5.28 
Madrid 137.6 9   7.28  2   5.61 
Navarre 127.7 7   5.25  7   18.24 
Basque Country 127.9 19   14.29  1   2.61 
Valencian Community 133.1 7   5.48  2   5.43 
n.c.  9     0    
*Minimum dose (1 day of treatment). / **5 days depending on dosage (Vademecum). /# Only 1working day.  
† We only have data on 135 NPW and 24 PW. 
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Table 3: Direct healthcare and indirect costs per patient (in euros) 
 
 NPW 
(n=170) 
PW 
(n=49) 
Direct Healthcare Cost (€)   
Medical visits 710.65 617.85 
Medication 4.45 4.03 
Diagnostic tests 55.45 16.56 
Hospitalisation (days) 3814.26 2222.8 
Indirect Cost (€)   
Work absenteeism 104.59 63.83 
Total Cost (€) 4689.4 2945.07 
 
Discussion  
 
The results of this study suggest that during the 
2009-2010 influenza pandemic, the management 
of NPW was more complicated than of PW, and 
the healthcare cost increased in NPW compared 
to PW. This result indicates the recommendation 
of extending the preventive protocol with vac-
cination to all women of childbearing age, and 
not only PW. 
Based on the primary data of non-vaccinated PW 
and NPW patients with a confirmed influenza A 
(H1N1) pdm09 diagnosis, we estimated the pat-
tern of healthcare resources utilisation and absen-
teeism from work of patients. The derived cost 
per patient and the economic impact on 
healthcare services were described. From an eco-
nomic point of view, and on an individual basis, 
NPW patients incurred more costs (€4,689.4 per 
patient) than PW patients (€2,945.07 per patient). 
From the healthcare provider's perspective, 81.34% 
of the national economic burden resulted from 
hospitalisations of NPW patients and 75.48% of 
PW patients. In our pandemic outbreak analysis, 
cost of hospitalisation had the strongest impact. 
From these results, the benefits of vaccination 
and other protection strategies could be benefi-
cial for both PW and NPW.  
Assuming that healthcare costs are an indirect in-
dicator of patient complications, this study re-
veals that Spanish PW were not at a higher risk of 
severe complications from influenza A 
(H1N1)pdm09 infection in 2009-2010 than NPW, 
which is not consistent with earlier reports on 
PW in other countries [6, 7, 26, 27]. As stated 
above, the Spanish Ministry of Health offered 
vaccination to the whole population, particularly 
to risk groups, which included PW. (10) Perhaps 
this is the reason why fewer PW were attended to 
if compared with other countries. Furthermore, 
our expected sample size became smaller. 
The healthcare utilisation description is essential 
for making an economic evaluation of health 
technologies and for estimating the burden of 
influenza A (H1N1) pdm09 in women of 
childbearing age. Every year, approximately 10-20% 
of the world population is infected by an influen-
za virus, which results in a significant number of 
outpatients and hospital visits, as well as a sub-
stantial economic burden for the healthcare sys-
tem and society. This study into PW and NPW in 
Spain has helped highlight influenza A (H1N1) 
pdm09, and recommends that all women of 
childbearing age should be considered in preven-
tive programmers, such as promoting vaccination 
in not only PW. 
These cost estimates were obtained from all 
women of childbearing age, of whom some were 
hospitalised for influenza A (H1N1) pdm09. 
The risk of serious complications was not high in 
patients with influenza A (H1N1) pdm09 if com-
pared with recent seasonal strains (30). Neverthe-
less, we found that NPW were at higher medical 
risk than PW. Thus longer hospitalisations might 
be attributed to differences in medical practice 
during a pandemic outbreak when clinical evolu-
tion is uncertain. In our study, the mean hospital-
isation stay required for NPW lasted over 7.55 
days, while it was 4.4 days for PW, which meant a 
higher healthcare cost for NPW. Our study offers 
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a detailed description of healthcare resources uti-
lisation for women of childbearing age, including 
medical assistance (such as home medical visits 
or occupational care visits), which are also rele-
vant for organising health services. 
In this study, antibiotics were prescribed to 32.65% 
of PW and to 55.88% of NPW. Since influenza is 
a viral infection, antibiotic prescriptions were 
probably inappropriate for most cases. Neverthe-
less, existing evidence does not clearly demon-
strate that antiviral drugs mitigate influenza com-
plications (31). 
The results of this study show the effectiveness of 
health care in both medical and patient treatment 
terms (PW and NPW) because all the patients re-
covered from influenza A (H1N1) pdm09. Length 
of absenteeism from work during the pandemic in 
Spain also exceeded that reported in other Euro-
pean countries (39). This is not an exclusive fea-
ture of pandemic influenza A (H1N1) pdm09 be-
cause it has also been observed in other patholo-
gies (33). 
The costs of pandemic influenza A (H1N1) 
pdm09 were clearly lower than the direct medical 
costs associated with other pathologies in Spain, 
such as metabolic syndrome (€1,900 million) and 
knee and hip osteoarthritis costs (€4,075 million) 
(34, 35). 
 
Limitations 
 
This study is not without its limitations. Firstly, 
the study population was a subsample of patients 
recruited for a case-control study. To correctly 
interpret the results, it is necessary to remember 
that the cases with this influenza had consulted 
their GP. Therefore, a significant association is 
expected to be found in the variables that influ-
enced the frequency of medical consultations in 
cases with influenza, which should produce no 
potential bias on the eligibility criteria and source 
population. Therefore, external validity might be 
compromised. However, patients were temporal-
ly representative of the pandemic surge in Spain 
(2), and the prevalence of comorbidities among 
our hospitalisations was similar to that previously 
reported (5, 6). Although the follow-up response 
was not 100%, the demographic characteristics of 
lost patients and those who continued in the 
study were not statistically different. Secondly, 
none of the recruited PW and NPW patients died 
during the influenza infection. Consequently, our 
cost estimates underestimate the actual impact of 
the pandemic, especially for treatments required 
because we did not have complete information 
on the doses employed. Therefore, we used a 1-
day minimum dose, except for Olseltamivir, 
whose minimum dose was 5 days. Nevertheless, 
most of the patients who died during the pan-
demic were either old or had previous severe 
chronic conditions, which barely affected our es-
timation of indirect costs (5, 36). Thirdly, we 
were able to analyse only the flu cases who had 
been in contact with health services and laborato-
ry-confirmed cases. This might have prevented us 
from overestimating costs due to influenza over 
diagnosis. However, it may have led us to under-
estimate the productivity costs among specific 
populations (housekeepers, non-contracted indi-
viduals, for instance) (37). Fourthly, despite there 
being evidence for possible differences in average 
costs according to social class (7), it was not pos-
sible to make comparisons by stratifying by this 
variable because many values were missing. Final-
ly, the limitations related with the sources of the 
data used in our study deserve further comment. 
Some of the information was collected directly 
from patients (patients or proxies) during inter-
views. In other cases, it was collected several 
months after having had influenza, which implies 
a high risk of recall bias. However, it probably 
lowered given the mass media repercussion that 
the 2009 influenza pandemic had (38). We had to 
consider alternative sources of information for 
unit costs because the Spanish National Health 
System has no accepted common information 
source (36). While the sources of unit costs for 
hospitals and days of absenteeism from work 
were reliable, many ambulatory unit costs were 
probably overestimated as they had been ob-
tained from the list of health services provision 
prices from third parties.  
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Finally, the power of the study may be insuffi-
cient to generalise (external validity) our results 
and further studies would be worthwhile. 
 
Conclusion 
 
The health cost for the number of persons af-
fected by influenza A (H1N1) pdm09 was con-
siderable compared with non-vaccinated individ-
uals. It is not clear as to whether and how the 
incidence of influenza A (H1N1) pdm09 will 
change in the future. Such changes will likely af-
fect the healthcare cost in both PW and NPW. 
 
Ethical considerations 
 
Ethical issues (including plagiarism, informed 
consent, misconduct, data fabrication and/or fal-
sification, double publication and/or submission, 
redundancy, etc.) have been completely observed 
by the authors 
 
Acknowledgments 
 
This project has been supported by Instituto de 
Salud Carlos III (Project GR09/0030). We thank 
all the physicians and interviewers in the partici-
pating hospitals for their collaboration. We are 
also grateful to all the women who participated in 
this study. The authors of this manuscript have 
no conflict of interest to declare. 
The members of the CIBERESP Cases and 
Controls in Pandemic Influenza Working 
Group are: Andalusia: E. Azor, J. Carrillo, R. 
Moyano, J.A. Navarro, M. Vázquez, F. Zafra 
(Red de Médicos Centinela, Andalusia), M.A. 
Bueno, M.L. Gómez, M. Mariscal, B. Martínez, 
J.P. Quesada, M. Sillero (Complejo Hospitalario 
de Jaén), M. Carnero, J. Fernández-Crehuet, J. del 
Diego Salas (Hospital Virgen de la Victoria), M. 
Delgado Rodríguez (CIBERESP, Universidad de 
Jaén), V. Fuentes (Hospital Costa del Sol), V. Ga-
llardo, E. Pérez (Servicio de Epidemiología, Junta 
de Andalucía), R. López (Hospital Infanta Elena, 
Huelva), J.R. Maldonado (Hospital de Torrecár-
denas), J.M. Mayoral (Servicio de Vigilancia de 
Andalucía), Á. Morillo (Hospital Virgen del Ro-
cío), J.M. Navarro, M. Pérez (Laboratorio de Re-
ferencia de Gripe), S. Oña (Hospital Carlos Haya), 
M.J. Pérez (Hospital Virgen de Valme), M.C. 
Ubago (Hospital Virgen de las Nieves), M. Zar-
zuela (Hospital Puerta del Mar). Valencian Com-
munity: J. Blanquer (Hospital Clínico Universita-
rio, Valencia), F. González Candelas (CIBERESP, 
CSISP-Universitat de Valencia), M. Morales (CI-
BERESP, CSISP-Universitat de Valencia, Hospi-
tal Doctor Peset). Castile and Leon: D. Carriedo, 
F. Díez, I. Fernández, S. Fernández, M.P. Sanz 
(Complejo Asistencial Universitario de León), J.J. 
Castrodeza, A. Pérez, S. Tamames (Dirección 
General de Salud Pública, Desarrollo e Innova-
ción, Junta de Castilla y León), V. Martín (CIBE-
RESP, Universidad de León), A. Molina (Institu-
to de Biomedicina, Universidad de León), J. Ortiz 
de Saracho (Hospital del Bierzo), R. Ortiz de Le-
jarazu (Centro Nacional de Gripe, Valladolid), A. 
Pueyo, J.L. Viejo (Complejo Asistencial, Burgos), 
P. Redondo (Servicio Territorial de Sanidad y 
Bienestar Social, León). Catalonia: A. Agustí, A. 
Torres, A. Trilla, A. Vilella (Hospital Clínic de 
Barcelona), J. Alonso (CIBERESP, Universitat 
PompeuFabra, IMIM-Instituto Recerca Hospital 
del Mar), F. Barbé (Hospital Arnau de Vilanova), 
M. Baricot, N. Soldevila (CIBERESP), L. Blanch, 
G. Navarro (Hospital de Sabadell), X. Bonfill, J. 
López-Contreras, V. Pomar, M.T. Puig (Hospital 
de Sant Pau), E. Borràs, A. Martínez, Núria Tor-
ner (Dirección General de Salud Pública, Genera-
litat de Catalunya), C. Bravo, F. Moraga (Hospital 
Valld’Hebrón), F. Calafell, O. Garín (Universi-
tatPompeuFabra), J. Caylà, C. Tortajada (Agencia 
de Salud Pública de Barcelona), À. Domínguez 
(CIBERESP, Universitat de Barcelona), I. Garcia, 
J. Ruiz (Hospital GermansTrias i Pujol), J.J. Gar-
cia (Hospital Sant Joan de Deu), (Universi-
tatPompeuFabra), J. Gea, J.P. Horcajada (Hospi-
tal del Mar), P. Godoy (CIBERESP, Departa-
ment de Salut Generalitat de Catalunya), N. Ha-
yes (Hospital Clínic-CRESIB), T. Pumarola 
(REIPI, Universitat de Barcelona), A. Rosell 
(Hospital de Bellvitge), M. Sáez (CIBERESP, 
Universitat de Girona). Madrid: Carlos Álvarez, 
M. Enríquez, F. Pozo (Hospital 12 de Octubre), J. 
Morales-Suárez-Varela et al.: Economic Evaluation of Health Services Costs During Pandemic Influenza … 
Available at:    http://ijph.tums.ac.ir                                                                                                        432 
Astray (Subdirección de Vigilancia, Comunidad 
de Madrid), F. Baquero, R. Cantón, J. C. Galán 
(CIBERESP, Hospital Ramón y Cajal), A. Robus-
tillo, M.A. Valdeón (Hospital Universitario Ra-
món y Cajal), E. Córdoba, F. Domínguez, J. Gar-
cía, R. Génova, E. Gil, S. Jiménez, M.A. Lopaz, J. 
López, F. Martín, M.L. Martínez,  M. Ordobás, E. 
Rodríguez, S. Sánchez, C. Valdés (Area de Epi-
demiología de la Comunidad de Madrid), J.R. Pa-
ño, M. Romero (Hospital Universitario La Paz),. 
Navarre: J. Castilla (CIBERESP, Instituto de Sa-
lud Pública de Navarra), P. Fanlo, F. Gil, V. Mar-
tínez Artola, M. Ruiz (Complejo Hospitalario de 
Navarra), J. Gamboa, F. Pérez-Afonso M. Sota, 
M.E. Ursua, M.T.Virto (Red de Médicos Centine-
la, Navarre), A. Martinez, L. Martínez (Instituto 
de Salud Pública, Navarre). Basque Country: U. 
Aguirre, A. Caspelastegui, P.P. España, S. García 
(Hospital Galdakao), J. Alustizac (Hospital Men-
daro), J.M. Antoñana, I. Astigarraga, J.I. Pijoan, I. 
Pocheville, M. Santiago, J.I. Villate (Hospital de 
Cruces), J. Arístegui, A. Escobar, M.I. Garrote 
(Hospital Basurto), A. Bilbao, C. Garaizar (Fun-
dación Vasca de Innovación e Investigación Sani-
tarias), G. Cilla, J. Korta, E. Pérez Trallero, C. 
Sarasqueta (Hospital Donostia), F. Esteban, J.L. 
Lobo, C. Salado, E. Tato (Hospital Txagorritxu), 
J.M. Quintana (CIBERESP, Fundación Vasca de 
Innovación e Investigación Sanitarias). 
 
Refrenes 
 
1. Sierra Moros MJ, Vázquez Torres M, Santa-
Olalla Peralta P, Limia Sánchez A, Cortes 
García M, Pachón Del Amo I (2010). Epide-
miological surveillance activities during the 
2009 influenza pandemic in Spain: lessons 
learnt one year after. Rev Esp Salud Pública, 
84(5): 463–79.  
2. Larrauri Cámara A, Jiménez-Jorge S, Simón 
Méndez L, de Mateo Ontañón S; Sistema de 
Vigilancia de Gripe en España (SVGE) 
(2010). Surveillance of influenza pandemic 
(H1N1) 2009 in Spain. Rev Esp Salud Pública, 
84(5): 569–88.  
3. Jamieson DJ, Honein MA, Rasmussen SA, Wil-
liams JL, Swerdlow DL, Biggerstaff MS, 
Lindstrom S, Louie JK, Christ CM, Bohm 
SR, Fonseca VP, Ritger KA, Kuhles DJ, Eg-
gers P, Bruce H, Davidson HA, Lutterloh E, 
Harris ML, Burke C, Cocoros N, Finelli L, 
MacFarlane KF, Shu B, Olsen SJ; Novel In-
fluenza A (H1N1) Pregnancy Working 
Group (2009). H1N1 2009 influenza virus in-
fection during pregnancy in the USA. Lancet, 
374(9688): 451-8.  
4. Centers for Disease Control and Prevention 
(CDC) (2012). Pregnant women and novel in-
fluenza A (H1N1) virus: considerations for 
clinicians. Available from: 
http://www.cdc.gov/h1n1flu/clinician_pr
egnant.htm  
5. Santa-Olalla Peralta P, Cortes-García M, Vicente-
Herrero M, Castrillo-Villamandos C, Arias-
Bohigas P, Pachon-del Amo I, Sierra-Moros 
MJ, Surveillance Group for New Influenza 
A(H1N1) Virus Investigation and Control 
Team in Spain (2010). Risk factors for disease 
severity among hospitalised patients with 
2009 pandemic influenza A (H1N1) in Spain, 
April–December 2009. Euro Surveill, 15(38). 
pii: 19667. 
6. Simmerman JM, Lertiendumrong J, Dowell SF, 
Uyeki T, Olsen SJ, Chittaganpitch M, Chun-
sutthiwat S, Tangcharoensathien V (2006).  
The cost of influenza in Thailand. Vaccine, 
24(20):4417-26. 
7. Lambert SB, Allen KM, Carter RC, Nolan TM 
(2008). The cost of community-managed viral 
respiratory illnesses in a cohort of healthy pre-
school-aged children. Respir Res, 9: 11.  
8. Schuchat A (2011). Reflections on pandemics, 
past and present. Am J Obstet Gynecol, 204(6 
Suppl 1):S4-6. 
9. Da Silva AA, Ranieri TM, Torres FD, Vianna 
FS, Paniz GR, Sanseverino PB, Picon PD, de 
Azevedo PB, Costa MH, Schuler-Faccini 
L, Sanseverino MT (2014). Impact on preg-
nancies in south Brazil from the influenza A 
(H1N1) pandemic: cohort study. PLoS One, 
9(2): e88624.  
10. Ministerio de Sanidad, Servicios Sociales e Igual-
dad (2012). Información importante sobre la 
gripe A (H1N1). Available from: 
http://www.msssi.gob.es/servCiudadanos/al
ertas/gripeAH1N1.htm 
11. Karageorgopoulos DE, Vouloumanou EK, Kor-
bila IP, Kapaskelis A, Falagas ME (2011). Age 
distribution of cases of 2009 (H1N1) pan-
Iran J Public Health, Vol. 45, No.4, Apr 2016, pp. 423-434  
433                                                                                                          Available at:  http://ijph.tums.ac.ir 
demic Influenza in comparison with seasonal 
influenza. PLoS One, 6(7): e21690. 
12. Torá-Rocamora I, Delclos GL, Martínez JM, 
Jardí J, Alberti C, Manzanera R, Yasui Y, 
Clèries R, Tobías A, Benavides FG (2012). 
Occupational health impact of the 2009 
H1N1 flu pandemic: surveillance of sickness 
absence. Occup Environ Med, 69(3): 205-10.  
13. Smith RD, Keogh-Brown MR, Barnett T, Tait J 
(2009). The economy-wide impact of pan-
demic influenza on the UK: a computable 
general equilibrium modelling experiment. 
BMJ, 339: b4571.  
14. Brouwers L, Cakici B, Camitz M, Tegnell A, Bo-
man M (2009). Economic consequences to 
society of pandemic H1N1 influenza 2009 - 
preliminary results for Sweden. Euro Surveill, 
14(37). pii: 19333. 
15. Keogh-Brown MR, Smith RD, Edmunds JW, 
Beutels P (2010). The macroeconomic impact 
of pandemic influenza: estimates from mod-
els of the United Kingdom, France, Belgium 
and The Netherlands. Eur J Health Econ, 
11(6): 543–54.  
16. Domínguez A, Alonso J, Astray J, Baricot M, 
Cantón R, Castilla J, Castro A, Delgado M, 
Godoy P, González-Candelas F, Martín V, 
Mayoral JM, Quintana JM, Perea E, Pumarola 
T, Soldevila N, Tamames S, Grupo de Traba-
jo del Proyecto CIBERESP de Casos y Con-
troles sobre la Gripe Pandémica (2011). Risk 
factors of Influenza (H1N1) 2009 hospi-
talization and effectiveness of pharmaceutical 
and nonpharmaceutical interventions in its 
prevention: a case-control study. Rev Esp Salud 
Pública, 85(1): 3-15.  
17. Pachón J, Falguera M, Gudiol F, Sabriá M, Álva-
rez-Lerma F, Cordero E (2010). Infecciones 
de las vías respiratorias Inferiores. Available 
from: 
https://www.seimc.org/contenidos/docume
ntoscientifcos/procedimientosclinicos/seimc-
procedimientoclinicoi.pdf  
18. Serrano-Herranz R (2010). Infecciones de las vías 
respiratorias Inferiores. Available from: 
https://www.fesemi.org/ 
19. Lynfield R, Davey R, Dwyer DE, Losso MH, 
Wentworth D, Cozzi-Lepri A, Herman-
Lamin K, Cholewinska G, David D, Kuetter 
S, Ternesgen Z, Uyeki TM, Lane HC, 
Lundgren J, Neaton JD; INSIGHT Influenza 
Study Group (2014). Outcomes of influenza 
A(H1N1)pdm09 virus infection: results from 
two international cohort studies. PLoS One, 
9(7): e101785. 
20. Hewagama S, Walker SP, Stuart RL, Gordon C, 
Johnson PD, Friedman ND, O'Reilly M, 
Cheng AC, Giles ML (2010). 2009 H1N1 in-
fluenza A and pregnancy outcomes in Victo-
ria, Australia. Clin Infect Dis, 50 (5): 686-90. 
21. Godoy P, Castilla J, Delgado-Rodríguez M et al. 
CIBERESP Cases and Controls in Pandemic 
Influenza Working Group, Spain (2012). Ef-
fectiveness of hand hygiene and provision of 
information in preventing influenza cases re-
quiring hospitalization. Prev Med, 54(6): 434-9.  
22. Castilla J, Godoy P, Domínguez Á, Martín V, 
Delgado-Rodríguez M, Martínez-Baz I, Bari-
cot M, Soldevila N, Mayoral JM, Astray J, 
Quintana JM, Cantón R, Castro A, González-
Candelas F, Alonso J, Saez M, Tamames S, 
Pumarola T; CIBERESP Cases and Controls 
in Influenza Working Group (2013). Risk fac-
tors and effectiveness of preventive measures 
against influenza in the community. Influenza 
Other Respir Viruses. 7(2): 177-183. 
23. Suh M, Kang DR, Lee DH, Choi YJ, Tchoe B, 
Nam CM, Kim HJ, Lee JK, Jun BY, Youm 
Y, Bae GN, Lee TY, Kim MS, Shin DC, Kim 
C (2013).  Socioeconomic burden of influenza 
in the Republic of Korea, 2007-2010. PLos 
One, 8(12): e84121. 
24. Galante M, Garin O, Sicuri E, Cots F, García-Al-
tés A, Ferrer M, Dominguez À, Alonso J 
(2012). Health services utilization, work ab-
senteeism and costs of pandemic influenza A 
(H1N1) 2009 in Spain: a multicenter-
longitudinal study. PLoS One, 7(2): e31696. 
25. Vademecum. CMP Medicom Editorial, S.A. 
(2010). Available from: 
http://www.vademecum.es  
26. Cots F, Chiarello P, García-Alzórriz E, Peláes E, 
Castells X, Raventós J (2010). Cost de l´activi-
tat asistencial. Variable de resultat per la gestió 
clínica. Fulls Econ, 39: 14-25 
27. Instituto Nacional de Estadística (INE) (2010). 
Encuesta anual de coste laboral 2008. 
http://www.ine.es/dyngs/INEbase/es/o
pera-
ra-
cion.htm?c=Estadistica_C&cid=12547360
Morales-Suárez-Varela et al.: Economic Evaluation of Health Services Costs During Pandemic Influenza … 
Available at:    http://ijph.tums.ac.ir                                                                                                        434 
60920&menu=resultados&idp=12547359
76596 
28. Instituto Catalán de Salud (2010) RESOLU-
CIÓN SLT/383/2009, de 21 de enero, sobre 
la revisión de precios públicos correspondien-
tes a los servicios sanitarios que presta el Insti-
tuto Catalán de la Salud. Diario Oficial de la 
Generalitat de Catalunya nº 5325. Available 
from: http://diario-oficial-generalitat-cata-
lunya.vlex.es/vid/revision-precios-sanitarios-
presta-81681102#  
29. Concejalía de Sanidad (2010). Precios públicos 
por las prestaciones de los servicios y activida-
des de naturaleza sanitaria de la red de centros 
de la comunidad de Madrid. Boletín Oficial 
de la Comunidad de Madrid ORDEN 
629/2009  
30. Sander B, Bauch CT, Fisman D, Fowler RA, 
Kwong JC, Maetzel A, McGeer A, Raboud J, 
Scales DC, Gojovic MZ, Krahn M (2010).  Is 
a mass immunization program for pandemic 
(H1N1) 2009 good value for money? Evi-
dence from the Canadian Experience. Vaccine, 
28(38): 6210-20.  
31. Burch J, Corbett M, Stock C, Nicholson K, Elliot 
AJ, Duffy S, Westwood M, Palmer S, Stewart 
L (2009). Prescription of anti-influenza drugs 
for healthy adults: a systematic review and 
meta-analysis. Lancet Infect Dis, 9(9): 537-45  
32. Gisbert JP, Cooper A, Karagiannis D, Hatlebakk 
J, Agréus L, Jablonowski H, Nuevo J (2009). 
Impact of gastroesophageal reflux disease on 
work absenteeism, presenteeism and produc-
tivity in daily life: a European observational 
study. Health Qual of Life Outcomes, 7: 90.  
33. Fairbrother G, Cassedy A, Ortega-Sanchez IR, 
Szilagyi PG, Edwards KM, Molinari NA, 
Donauer S, Henderson D, Ambrose S, Kent 
D, Poehling K, Weinberg GA, Griffin MR, 
Hall CB, Finelli L, Bridges C, Staat MA, New 
Vaccine Surveillance Network (NVSN) 
(2010). High costs of influenza: Direct medi-
cal costs of influenza disease in young chil-
dren. Vaccine, 28(31): 4913-9.  
34. Donaldson LJ, Rutter PD, Ellis BM, Greaves 
FE, Mytton OT, Pebody RG, Yardley IE 
(2009). Mortality from pandemic A/H1N1 
2009 influenza in England: public health sur-
veillance study. BMJ, 339: b5213. 
35. Xue Y, Kristiansen IS, de Blasio BF (2010). 
Modeling the cost of influenza: the impact of 
missing costs of unreported complications 
and sick leave. BMC Public Health, 10: 724.  
36. Duncan B (2009). How the media reported the 
first days of the pandemic (H1N1) 2009: re-
sults of EU-wide media analysis. Euro Surveill, 
14(30): 19286.  
37. ANZIC Influenza Investigators, Webb SA, Pet-
tilä V, Seppelt I, Bellomo R, Bailey M, Cooper 
DJ, Cretikos M, Davies AR, Finfer S, Harri-
gan PW, Hart GK, Howe B, Iredell JR, 
McArthur C, Mitchell I, Morrison S, Nichol 
AD, Paterson DL, Peake S, Richards B, Ste-
phens D, Turner A, Yung M (2009). Critical 
care services and 2009 H1N1 influenza in 
Australia and New Zealand.  N Engl J Med, 
361(20): 1925–34. 
38. Fraser C, Donnelly CA, Cauchemez S et al. 
WHO Rapid Pandemic Assessment Collabo-
ration (2009). Pandemic potential of a strain 
of influenza A (H1N1): early findings. Science, 
324(5934): 1557-61.  
 
 
 
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.
